7 years ago

Wren Therapeutics Secures £18 Million Series A Funding

  • Wren Therapeutics, a Cambridge, UK-based biopharmaceutical company focused on drug discovery and development for protein misfolding diseases, has completed a £18 million Series A financing round led by The Baupost Group with participation from LifeForce Capital and high net worth individual investors

  • The company intends to use the funds to accelerate its pipeline for protein misfolding diseases

  • Wren is a spin-off company from the University of Cambridge (UK) and Lund University (Sweden) focused on drug discovery and development for protein misfolding diseases

  • Wren is advancing a broad pipeline of small molecule and antibody therapeutics, as well as diagnostics, spanning neurology, ophthalmology and metabolic diseases

  • The company is based at the University of Cambridge, in the recently opened Chemistry of Health Centre, and plans on opening a satellite office in Boston, Massachusetts in the near term.

      • ProblemHealthcare

      "Protein misfolding diseases, such as Alzheimer’s, Parkinson’s, Huntington’s, and Amyotrophic Lateral Sclerosis (ALS), are a major burden on healthcare systems. There are currently no cures for these diseases, and the existing treatments are often ineffective or have serious side effects. "

      Solution

      "Wren Therapeutics is developing novel therapies for protein misfolding diseases. Their approach focuses on targeting the underlying cause of these diseases, which is the misfolding of proteins. They are developing a broad pipeline of small molecule and antibody therapeutics, as well as diagnostics, spanning neurology, ophthalmology and metabolic diseases."

      Covered on